FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial. PMID 41429128 · Lancet Oncol · 2026-Feb The trial compares two imaging modalities (FET-PET vs CE-T1MRI) for target volume delineation in re-irradiation, not a drug intervention. The phase is not explicitly stated in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Surgical timing in advanced ovarian cancer during the TRUST trial era: A systematic review, meta-analysis and study-level meta-regression of randomized controlled trials. PMID 41420991 · Eur J Surg Oncol · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trial. PMID 41418627 · Int J Gynecol Cancer · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Re: M. Roupret, A. Bertaut, G. Pignot, et al. ALBAN (GETUG-AFU 37): A Phase 3, Randomized, Open-label, International Trial of Intravenous Atezolizumab and Intravesical Bacillus Calmette-Guérin (BCG) Versus BCG Alone in BCG-naive High-risk, Non-muscle-invasive bladder cancer (NMIBC). Ann Oncol. In press. https://doi.org/10.1016/j.annonc.2025.09.017. PMID 41402160 · Eur Urol Oncol · 2026-Feb The record is a letter to the editor (Re:) commenting on a primary trial report (ALBAN/GETUG-AFU 37) in press. It is not the original result report of the randomized trial. While it describes the trial's design (Phase 3, randomized, drug intervention), it does not provide the primary efficacy results or time-to-event endpoints (Kaplan-Meier, HR) required for eligibility. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Is neoadjuvant therapy necessary for resectable pancreatic cancer? A review of randomized controlled trials to date: a narrative review. PMID 41366146 · Int J Clin Oncol · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Laparoscopic versus open pancreatoduodenectomy: a pilot randomized trial in a developing African country. PMID 41345531 · Surg Endosc · 2026-Feb 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials. PMID 41344351 · Lancet Gastroenterol Hepatol · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of a resilience model-based cancer prehabilitation program in patients with newly diagnosed colorectal cancer: A randomized controlled trial. PMID 41319525 · Eur J Oncol Nurs · 2026-Feb Study is an original RCT in oncology but does not meet key eligibility criteria: it lacks a drug-containing intervention (focus is on a resilience-based prehabilitation program) and does not report a primary/key time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, KM curve, or HR). Outcomes are patient-reported resilience, symptoms, and spiritual well-being, which are not time-to-event efficacy endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial - BREASTIMMUNE-03. PMID 41314029 · Breast · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Bibliometric analysis of anti-angiogenic therapy in gastric cancer: research hotspots, trends, and emerging frontiers. PMID 41284207 · Int J Clin Pharm · 2026-Feb The record is a bibliometric review analyzing research trends, not an original clinical trial report. It lacks primary time-to-event efficacy data from a randomized trial. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Single dose perioperative intravesical instillation of gemcitabine versus mitomycin-C following resection of non-muscle invasive bladder cancer: A randomized controlled trial. PMID 41266181 · Urol Oncol · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Eliciting Unreported Subgroup-Specific Survival from Aggregate Randomized Controlled Trial Data. PMID 41230837 · Med Decis Making · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Increasing Phytochemical-rich Foods and Lactobacillus Probiotics in Men with Low-risk Prostate Cancer-A Randomised, Double-blind, Placebo-controlled Trial. PMID 41152052 · Eur Urol Oncol · 2026-Feb The trial is randomized, original, and in oncology (prostate cancer), but the intervention is dietary (phytochemicals and probiotics), not a drug-containing intervention. The primary endpoint is PSA progression, not a time-to-event efficacy endpoint like OS/PFS/DFS. The phase is not explicitly stated as Phase III/IIIb or II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Treatment Intensification with Hepatic Arterial Infusion Chemotherapy in Patients with Liver-Only Colorectal Metastases Still Unresectable After Systemic Induction Chemotherapy: Exploratory Findings From a Prematurely Closed Multicenter Randomized Phase II Study: SULTAN UCGI 30/PRODIGE 53 (NCT03164655). PMID 41118066 · Ann Surg Oncol · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo). PMID 41115467 · Ann Oncol · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial. PMID 41110700 · Ann Oncol · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Target trial on the outcomes of laparoscopic compared to robotic-assisted proctectomy in stage II-III rectal cancer. PMID 41099918 · Updates Surg · 2026-Feb 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of 177Lu-FAPI-XT radioligand therapy in patients with advanced sarcoma and other cancer entities: first-in-human, dose-escalation study. PMID 41087606 · Eur J Nucl Med Mol Imaging · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial. PMID 41086386 · J Clin Oncol · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guérin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial. PMID 41084757 · Eur Urol · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Comments on Hong et al "Radiotherapy versus imiquimod for complex lentigo maligna: A phase 3 randomized clinical trial". PMID 41076128 · J Am Acad Dermatol · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study. PMID 41062389 · Eur Urol · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [18F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 Trial. PMID 41032077 · Eur J Nucl Med Mol Imaging · 2026-Feb The record describes a Phase 3 randomized trial in multiple myeloma with a drug intervention, but the reported results are exclusively about imaging method validation (CT/PET metrics, correlations with clinical parameters, response). It does not report any primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, nor does it include Kaplan-Meier estimates or hazard ratios for survival outcomes. Therefore, it does not meet the inclusion criterion for a primary/key secondary time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making. PMID 41005700 · Value Health · 2026-Feb 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
B
|
旧查询独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Re: Metformin for Patients with Metastatic Prostate Cancer Starting Androgen Deprivation Therapy: A Randomised Phase 3 Trial of the STAMPEDE Platform Protocol. PMID 40925750 · Eur Urol · 2026-Feb Title indicates a randomized Phase 3 trial, but no abstract or text is provided to confirm a drug-containing intervention (e.g., metformin) and a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). Cannot establish eligibility without explicit evidence of these criteria. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Trabectedin maintenance therapy after liposomal doxorubicin plus trabectedin combination in patients with relapsed ovarian cancer: the randomized, phase II TRAMANT study. PMID 40517132 · Int J Gynecol Cancer · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer. PMID 40335398 · Eur Urol Oncol · 2026-Feb The record describes a secondary, patient-reported quality-of-life analysis from the PROFIT Phase III trial comparing radiotherapy regimens. While the parent trial is a definitive Phase III randomized oncology trial in humans, this specific publication does not report on a drug-containing intervention (radiotherapy only) and does not report on a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it is not eligible for the cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Medical tumor therapy for head and neck cancer: between standardization and personalization]. PMID 40261344 · HNO · 2026-Feb The record is a review article summarizing developments and mentioning results from multiple phase III studies, not an original formal-result report of a single randomized trial with a primary time-to-event endpoint. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Effects of Web-Based Decision Aid to Support Cervical Cancer Screening Decision Among Young Working Women: A Pilot Randomised Controlled Trial. PMID 39739299 · Int J Behav Med · 2026-Feb The study is a randomized pilot trial in oncology (cervical cancer screening), but it evaluates a non-drug intervention (web-based decision aid vs. fact sheet) and its primary efficacy outcome is screening uptake, not a time-to-event endpoint like OS or PFS. Phase is not specified but is likely Phase II/III or pilot; however, the lack of a drug intervention and time-to-event endpoint excludes it. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer. PMID 42421558 · Ann Med · 2026-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Comparison of Transumbilical Single‑Port and Multi‑Port Laparoscopic Myomectomy in Patients with Uterine Fibroids: Effects on Stress Response, Immune Function, and Incision Cosmetic Outcomes. PMID 42294769 · J Invest Surg · 2026-Dec 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Modeling Disease-specific Survival in Observational Studies with Missing Cause of Death: Leveraging Information from Clinical Trial Data. PMID 42281757 · Comput Stat Data Anal · 2026-Dec The record describes a methodological paper for inferring disease-specific survival in observational studies using data from a randomized trial (NSABP B-06). While it references a randomized oncology trial with a time-to-event endpoint, the paper itself is not a report of that trial's results; it is a methodological study. No drug intervention is explicitly mentioned in the abstract. Therefore, it does not meet the criteria for inclusion as an original formal-result report of a randomized trial with a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness of pembrolizumab plus chemotherapy for metastatic non-small cell lung cancer: a head-to-head trial vs. real-world comparison. PMID 41949826 · J Med Econ · 2026-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States. PMID 41730003 · J Med Econ · 2026-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myeloma. PMID 41701105 · J Med Econ · 2026-Dec This record is an indirect treatment comparison/synthesis of data from multiple trials (PERSEUS, CASSIOPEIA, Myeloma XI), not an original formal report of a single Phase III/IIIb or Phase II/III randomized trial. It does not meet the 'original_result' criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Renin-angiotensin-aldosterone system inhibitors and risk of pancreatic cancer in older adults: A target trial emulation. PMID 41872700 · Int J Cancer · 2026-Aug-15 The record is an observational study using a target trial emulation framework with propensity score matching, not a randomized controlled trial. It does not report a trial phase (Phase II/III or Phase III/IIIb) and is not an original result from a randomized trial. Therefore, it does not meet the criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-Term Effects of High-Intensity Training after Lung Cancer Surgery-A 5-Yr Follow-Up of a Randomized Controlled Trial. PMID 41851742 · Med Sci Sports Exerc · 2026-Aug-01 The study is a randomized trial in lung cancer patients with survival as a time-to-event endpoint, but it lacks a drug-containing intervention (exercise-based intervention) and does not establish Phase III/IIIb or Phase II/III evidence. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized Study on Different Radiation Doses in Neoadjuvant Chemoradiation Therapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma (Neo-DRATEC Trial). PMID 41713514 · Int J Radiat Oncol Biol Phys · 2026-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors. PMID 42433301 · Eur Urol Open Sci · 2026-Aug The record describes the design of a Phase 4 trial (ITALIC-RCC) as a protocol, not a report of results from a Phase III/IIIb or Phase II/III randomized trial. Therefore, it does not meet the eligibility criteria for a result report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparative safety of postoperative HIPEC with recombinant mutant TNF-α versus paclitaxel for gastric cancer peritoneal metastasis: a randomized controlled trial. PMID 42391679 · Surg Oncol · 2026-Aug The study is a randomized trial in gastric cancer with drug intervention, but it is not confirmed as a definitive phase (Phase III/IIIb or II/III) and does not have a primary/key secondary time-to-event efficacy endpoint as the focus; it is primarily a safety study. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Five-year survival after minimally invasive versus open gastrectomy: A meta-analysis of randomized controlled trials with trial sequential analysis. PMID 42364595 · Surg Oncol · 2026-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial. PMID 42364416 · Breast · 2026-Aug The report is a subgroup analysis (exploratory by HER2 status) of a randomized trial. While the trial may be Phase III, this specific publication is not the original formal result report of the primary trial endpoint; it is a pre-specified or exploratory subgroup analysis, which is excluded per the adjudication criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer. PMID 42330688 · Breast · 2026-Aug The record describes a single-arm Phase IIIb study. While it meets most other criteria (oncology, human, Phase III, drug intervention, time-to-event endpoints, original results), the absence of randomization makes it ineligible per the specified criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| External vacuum expansion in autologous fat transfer as total breast reconstruction: Is it worth it? The interim analysis of the multicentre randomised controlled EVE trial. PMID 42314328 · J Plast Reconstr Aesthet Surg · 2026-Aug The study is a randomized, oncology-related human trial, but it is excluded because it lacks a primary/key secondary time-to-event efficacy endpoint (like OS, PFS, DFS) and does not involve a drug intervention. The endpoints are volumetric outcomes and safety, which are not time-to-event. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Overall Survival of Patients With PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP DNA Vaccine Versus Placebo. PMID 42303538 · Clin Genitourin Cancer · 2026-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Mind the Gap: Impact of New Labels on Public Perceptions and Calculated Risk of Adverse Outcomes after a Melanoma In Situ Diagnosis-A Secondary Analysis of an Online Randomized Experiment. PMID 42289825 · Med Decis Making · 2026-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Mixture cure model analysis of event-free survival in the NIAGARA Trial: Quantifying the cure fraction benefit of perioperative durvalumab in muscle-invasive bladder cancer. PMID 42247881 · Urol Oncol · 2026-Aug The record describes an exploratory statistical analysis (mixture cure model) of reconstructed individual patient data from the NIAGARA trial. The metadata (publication types, MeSH) indicates a 'Randomized Controlled Trial' but does not explicitly state the trial phase as Phase III/IIIb or Phase II/III. Furthermore, this is not an original formal-result report of the trial itself; it is a secondary analysis using reconstructed data to explore cure fractions. Therefore, while individual criteria (oncology, human, randomized, drug intervention, time-to-event) are met, the report is not an eligible original trial result. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules. PMID 42217273 · Clin Genitourin Cancer · 2026-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Delayed Progression-Free Survival Benefit of Belzutifan Versus Everolimus in LITESPARK-005: A Reconstructed Time-to-Event Reanalysis. PMID 42150922 · Clin Genitourin Cancer · 2026-Aug This is a secondary, reconstructed-data reanalysis of the LITESPARK-005 trial, not an original formal-result report of a Phase III trial. The metadata does not confirm the trial phase, and the analysis itself is a post-hoc statistical exploration of nonproportional hazards. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pelvic nodes ultra-hypo fractionated versus conventionally fractionated IMRT with HDR brachytherapy in prostate cancer: interim analysis of a collaborative multi-institutional non-inferiority phase 3 trial (PCS-XI, NCT05820633). PMID 42134662 · Radiother Oncol · 2026-Aug The report is an interim analysis of a phase III randomized trial in oncology with a drug intervention (ADT), but it explicitly focuses on toxicity and patient-reported outcomes, not on a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The conclusion states longer follow-up is required to assess oncologic outcomes. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |